Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The true incidence rate is uncertain
Reduce the dose or stop if you notice symptoms, and hydrate well
Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
If you have any kind of chronic disease or a history of diabetes, hypertension, anxiety and depression, kidney problems, mental health issues, or allergic reactions, please inform your doctor and take appetite-control supplements on his/her recommendation only
As a brand, its core identity revolves around supplying researchers with reliable, verified ingredients that support molecular inquiry, not therapeutic treatment
